YD Bio Limited closed at $7.18 on Nov 5, up 3.31%, 53.4% below its 52-week closing high. Volume of 77.0K shares was 0.67× its 20-day average (below normal).
Split-adjusted performance: +22.1% over one month, +35.7% over six months, -34.0% over one year.
Short interest was 192.2K shares at the Oct 15 settlement, up 8.4% from the prior report (1.4% of float, 1.0 days to cover).
No reported quarters with price history yet.
Not enough peers to rank
No recent articles focused on YD Bio Limited. 4 articles mention it in passing.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
